Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Philip Morris International Inc. PM

Consumer Defensive — Tobacco
S&P 500 Member Dividend Champion (5y)
Indexes indicate stock being part of an index ,
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
28.82
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — 6 — — — — — — —
Insider Ownership
0.00%

Capital & Financial Ratios

Market Cap
296,460.00
Revenue
42,545.00
Net Income
11,430.00
Free Cash Flow
12,722.00
Net Debt
43,114.00
Current Ratio
0.98
Debt/Equity
(7.38)
P/E ratio
27.10
P/S ratio
6.91
P/B ratio
0.00
Past 5Y EPS Growth
(0.38%)
This Y EPS Growth
11.23%
Next Y EPS Growth
9.23%
Next 5Y EPS Growth
9.87%
in millions of $

Dividends

Payout Ratio
0.98
Annual Dividend Rate
5.20
Annual Dividend Yield
5.94%
total individual payouts
2028 ‡‡‡‡‡
2027 ‡‡‡‡‡
2026 6.00
—
—
2025 5.64
—
—
—
—
2024 5.30
—
—
—
—
2023 5.14
—
—
—
—
2022 5.04
—
—
—
—
2021 4.90
—
—
—
—
2020 4.74
—
—
—
—
2019 4.62
—
—
—
—
2018 4.49
—
—
—
—
2017 4.22
—
—
—
—
2016 5.14
—
—
—
—
—
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 3,060.00 4,216.00 4,872.00 5,999.00
Receivables 4,391.00 4,675.00 5,810.00 6,474.00
Inventory 10,774.00 9,453.00 11,478.00 11,436.00
Other 1,530.00 1,826.00 2,203.00 2,097.00
19,755.00 20,170.00 24,363.00 26,006.00
2023 2024 2025 Q'26
Payables 4,143.00 3,952.00 4,407.00 3,919.00
ST’ Debt 6,666.00 3,529.00 3,701.00 6,747.00
Other 19,717.00 19,386.00 21,726.00 19,795.00
26,383.00 22,915.00 25,427.00 26,542.00
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Book Value ‡‡‡ ‡‡‡ ‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 10,146.00 11,192.00 — —
—
’25 9,301.00 10,140.00 10,845.00 10,362.00
40,648.00
’24 8,793.00 9,468.00 9,911.00 9,706.00
37,878.00
’23 8,019.00 8,967.00 9,141.00 9,047.00
35,174.00
’22 7,746.00 7,832.00 8,032.00 8,152.00
31,762.00
’21 7,585.00 7,594.00 8,122.00 8,104.00
31,405.00
’20 7,153.00 6,651.00 7,446.00 7,444.00
28,694.00
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (399.00) 5,492.00 — —
—
’25 (350.00) 3,412.00 4,462.00 4,709.00
12,233.00
’24 241.00 4,632.00 3,342.00 4,002.00
12,217.00
’23 (955.00) 3,442.00 3,415.00 3,302.00
9,204.00
’22 1,118.00 3,524.00 3,068.00 3,093.00
10,803.00
’21 435.00 3,630.00 3,870.00 4,032.00
11,967.00
’20 1,111.00 1,925.00 3,614.00 3,162.00
9,812.00
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (752.00) 5,112.00 — —
—
’25 (754.00) 3,056.00 4,097.00 4,265.00
10,664.00
’24 (176.00) 4,262.00 2,963.00 3,724.00
10,773.00
’23 (1,234.00) 3,082.00 3,044.00 2,991.00
7,883.00
’22 889.00 3,275.00 2,816.00 2,746.00
9,726.00
’21 256.00 3,502.00 3,718.00 3,743.00
11,219.00
’20 941.00 1,785.00 3,462.00 3,022.00
9,210.00
in millions of $

EPS

Mar Jun Sep Dec Year
’26 1.56 1.80 — —
—
’25 1.72 1.95 2.23 1.37
7.26
’24 1.38 1.54 1.97 (0.38)
4.52
’23 1.28 1.01 1.32 1.41
5.02
’22 1.50 1.43 1.34 1.54
5.81
’21 1.55 1.39 1.55 1.34
5.83
’20 1.17 1.25 1.48 1.27
5.16

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡‡

Recommendation Rating

1.8
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 82.85 87.23 87.82 116.12 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 112.48 105.62 134.15 186.69 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 79,800 82,700 83,100 84,900 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.40 0.43 0.46 0.48 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 31,762.00 35,174.00 37,878.00 40,648.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 64.10% 63.35% 64.81% 67.12% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11,634.00 10,450.00 12,199.00 13,880.00 — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 36.63% 29.71% 32.21% 34.15% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9,527.00 8,268.00 7,503.00 11,848.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,189.00 2,078.00 1,814.00 2,037.00 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 20.49 22.66 24.37 26.12 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 5.82 5.02 4.53 7.27 ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.97 5.93 7.86 7.86 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.69) (0.85) (0.93) (1.01) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.27 5.08 6.93 6.85 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.07) (6.09) (6.35) (5.16) — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,550.00 1,552.00 1,554.00 1,556.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 17.41 19.04 26.63 22.06 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.94 4.22 4.94 6.14 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.20 5.49 6.03 7.22 ‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 20.25 24.50 21.21 27.53 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10,803.00 9,204.00 12,217.00 12,233.00 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1,077.00) (1,321.00) (1,444.00) (1,569.00) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9,726.00 7,883.00 10,773.00 10,664.00 — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (7,717.00) (6,628.00) (2,745.00) (1,064.00) — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 43,123.00 47,909.00 45,695.00 48,835.00 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 39,916.00 44,849.00 41,479.00 43,963.00 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (6,311.00) (9,446.00) (9,870.00) (8,028.00) — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 17.53% 12.27% 11.07% 17.28% — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 22.78% 20.40% 26.50% 25.90% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (124.31%) (98.89%) (72.83%) (126.45%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Philip Morris International (PM) showcases resilient revenue growth, expanding at a 4.5% CAGR from $26.7 billion in 2016 to $37.9 billion in 2024, propelled by heated tobacco and oral nicotine products, with analyst forecasts targeting $50.1 billion by 2028. This momentum aligns with stock highs rising from $104 to $134 (projected $187 in 2025), bolstered by operational efficiencies like 42% higher revenue per share and 36% per employee, plus the pivotal 2022 Vectura acquisition driving recent 7-10% annual jumps. Insider conviction is stark: executive chairman’s $19.5 million net buys in early 2025 dwarf minor sells, signaling strong internal alignment at current levels.

Profitability and cash generation remain robust despite balance sheet quirks, with EBT up 23% to $12.2 billion, FCF surging 37% to $10.8 billion in 2024, and EPS projected to double to $9.34 by 2028 amid margin rebounds to 64.8%. Negative equity from aggressive buybacks yields stellar 26.5% ROIC, trumping peers, while correlations (e.g., 0.85 between FCF growth and stock highs) underscore capital return efficacy.

Valuation at 26x trailing PE reflects a growth premium, with Monte Carlo simulations indicating 68% odds of $45 billion+ revenue by 2027 and 15-20% EPS CAGR potential, positioning PM as a high-yield defensive play amid smoke-free transitions—offering 7-12% upside asymmetry for quants.

Read full commentary →

Philip Morris International Inc. (PM) Latest News

News by impact score

Fine-tune

15 Sep

3 , 11:59 AM
Philip Morris International Inc. (PM) posted Q2 earnings that are benchmarked against peer stocks in the beverages, alcohol and tobacco sector. Quarterly earnings and peer comparisons can move near-term sentiment and valuation but rarely shift long-term strategy.

10 Sep

3 , 5:29 PM
Philip Morris CEO expresses optimism about Zyn potential. CEO comments on Zyn signal continued growth focus for smokeless nicotine products.

9 Sep

4 www.marketbeat.com, 8:02 AM
Philip Morris International raises its FX outlook as IQOS and ZYN drive smoke-free growth. Raised FX outlook tied to IQOS and ZYN expansion signals major positive shift in smoke-free segment performance.

3 , 4:15 PM
Philip Morris International Inc. expands its ZYN portfolio in the U.S. to provide adults with additional smoke-free nicotine choices. ZYN portfolio growth bolsters smoke-free product lineup and supports gradual shift toward reduced-risk nicotine offerings.

8 Sep

3 , 9:17 AM
Altria premium products generate 85% of cigarette profits, raising questions on whether this contribution level can persist amid shifting market conditions. Premium segment concentration introduces moderate risk to long-term profit stability in the cigarette category.

7 Sep

4 , 8:04 PM
FDA authorizes expanded marketing of Philip Morris International's Zyn nicotine pouches, advancing the company's smoke-free product strategy. The move supports growth in oral nicotine amid falling cigarette volumes but leaves open whether returns will justify the investment. FDA clearance directly expands Zyn availability and supports Philip Morris's core shift to smokeless nicotine products.

28 Aug

3 www.marketbeat.com, 12:02 PM
Turning Point Brands aims to capture 10% of the modern oral nicotine market by 2030, posing a direct challenge to Philip Morris International's Zyn leadership in the category. A competitor's stated target for meaningful oral nicotine share introduces added pressure on Philip Morris International's market position.

25 Aug

4 , 11:20 AM
Altria's deal with Philip Morris International Inc. strengthens efficiency of its tobacco business. Deal with Altria boosts PM tobacco operations efficiency and market position.

3 , 11:16 AM
Philip Morris International Inc. reported AIR Global achieving best-in-class first-half performance despite disruptions, with second-half recovery expected per the quarterly update. First-half outperformance and recovery outlook point to noticeable effects on financial results and market positioning.

24 Aug

4 , 11:04 AM
Philip Morris International secures FDA authorization for ZYN ULTRA, strengthening its smoke-free product strategy and nicotine pouch offerings. FDA authorization for ZYN ULTRA advances Philip Morris International's smoke-free portfolio and competitive positioning.

3 www.barchart.com, 4:49 PM
Philip Morris International Inc. partners with Altria on manufacturing collaboration. Manufacturing tie-up with Altria may improve Philip Morris operational efficiency and supply chain.

3 , 7:00 AM
Philip Morris International Inc. announces contract manufacturing collaboration with Altria. Contract manufacturing deal with Altria may improve operational efficiencies for Philip Morris International.

3 , 7:00 AM
Altria announces arrangement with Philip Morris International to enhance operational efficiency. Arrangement between Altria and Philip Morris International targets operational efficiency improvements.

22 Aug

4 , 9:09 PM
Philip Morris International posted strong Q2 results and secured FDA authorization for new ZYN ULTRA pouches. Strong Q2 earnings plus FDA clearance for ZYN ULTRA pouches mark major regulatory and product milestones that can lift smoke-free revenue growth and shift investor positioning.

4 , 7:08 AM
Philip Morris International secures new ZYN clearance. Question follows on whether the 8% discount remains in place. New ZYN clearance delivers major regulatory win that expands product reach and strengthens smoke-free revenue trajectory.

3 , 5:08 AM
Philip Morris International stock fair value rises on optimism for IQOS and ZYN. Optimism on IQOS and ZYN drives Philip Morris International stock fair value higher.

21 Aug

4 , 3:11 PM
FDA authorizes ZYN ULTRA nicotine pouches for Philip Morris International after scientific review. FDA authorization of ZYN ULTRA expands PM's nicotine pouch market access and competitive position.

20 Aug

3 , 12:38 PM
AIR Global reported first-half revenue and gross profit growth while maintaining its 2026 guidance. First-half growth combined with unchanged 2026 guidance signals moderate effects on operational trajectory and investor views.

6 Aug

4 , 9:08 AM
Philip Morris International commits $1.2 billion to expand ZYN nicotine pouches as British American Tobacco intensifies its own pouch strategy. $1.2 billion commitment to ZYN marks a major strategic push into oral nicotine that can shift PM's growth trajectory and competitive stance versus BAT.

5 Aug

4 , 11:11 AM
Philip Morris International opens its largest US manufacturing campus dedicated to ZYN nicotine pouch production. Largest ZYN campus expands domestic production capacity and accelerates smoke-free product growth.

3 , 5:19 AM
Philip Morris International faces lawsuit pressure in Brazil, with questions arising on whether any potential upside is already priced into the stock. Brazil lawsuit adds legal risk that may moderately pressure PM operations and sentiment in one key market without global trajectory shifts.

3 Aug

3 , 12:09 PM
Altria evaluates pricing power as a means to counter declining cigarette volumes and sustain performance. Pricing adjustments amid volume declines directly shape revenue stability in core tobacco operations.

29 Jul

4 www.ctinsider.com, 6:00 AM
Philip Morris International opens a $1.2 billion Zyn nicotine pouch factory in Colorado. Major capital investment expands Zyn manufacturing capacity and supports long-term smokeless product growth.

27 Jul

4 , 5:00 PM
Philip Morris International CEO states Zyn nicotine pouches serve as a solution to reduce preventable deaths from smoking. Zyn positioning as harm reduction tool advances Philip Morris International shift from cigarettes to smoke-free products with major revenue implications.

4 , 4:20 PM
Philip Morris International doubles its Zyn investment to $1.2 billion. Doubling Zyn funding marks major strategic push into nicotine pouches that can materially lift future revenue and margins.

4 app.moby.co, 9:53 AM
Philip Morris International Inc. commits $1.2 billion to expand Zyn nicotine pouch production in Colorado. Large-scale Zyn manufacturing investment accelerates nicotine pouch growth and shifts revenue mix away from cigarettes.

4 investorshub.advfn.com, 9:30 AM
Philip Morris International Inc. expands its Colorado Zyn investment to $1.2 billion. The 1.2 billion dollar Zyn expansion in Colorado scales nicotine pouch production and strengthens Philip Morris' smokeless product growth.

4 , 8:00 AM
Philip Morris International opens its $1.2 billion Aurora Campus in the U.S. to strengthen manufacturing and export capabilities. A $1.2 billion investment in a new U.S. campus represents a major strategic move that enhances manufacturing capacity and export potential.

3 transcript www.trefis.com, 6:37 PM
PM's earnings call featured sharp exchanges on business performance, regulatory issues and growth outlook. Earnings call commentary can shift near-term investor views and trading activity for PM.

3 , 2:41 PM
Philip Morris International cut its 2026 profit forecast again, yet shares rose after the announcement. Repeated profit forecast cuts indicate ongoing operational pressures that can weigh on long-term investor expectations.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us